All In Biotech

Drug Trial Radar · NCT06780670

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 443 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

443

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Jun 27, 2028

Study completion Jul 19, 2033

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Conditions

  • Prostate Cancer

Interventions

  • Investigators choice of SoCDrug

    The control treatment in Phase III is investigator's choice of SoC

  • AAA817Drug

    The investigational treatment is AAA817

  • AAA817Drug

    The investigational treatment is AAA817

  • AAA817Drug

    Investigational treatment is the Dose B of AAA817

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemical response rate (Phase II)Time frame: from date of randomization up to approximately 24 months
  2. Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase IITime frame: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
  3. Tolerability of the proposed dose of AAA817- Phase IITime frame: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
  4. Radiographic progression-free survival (rPFS)- Phase IIITime frame: from date of randomization up to approximately 24 months
  5. Overall survival (OS)- Phase IIITime frame: from date of randomization up to approximately 24 months

Locations

93 sites in 13 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • VA Greater LA Healthcare System

    Los Angeles, California · Recruiting

  • VA Palo Alto Health Care System

    Palo Alto, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Recruiting

  • Saint Johns Cancer Institute

    Santa Monica, California · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Baptist Health South

    Miami, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • University Cancer and Blood Center LLC

    Athens, Georgia · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • University of Kansas Hospital

    Kansas City, Kansas · Recruiting

  • East Jefferson Hospital

    Metairie, Louisiana · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • WA Uni School Of Med

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • New Jersey Urology LLC

    Voorhees Township, New Jersey · Recruiting

  • Mount Sinai Hosp Med School

    New York, New York · Recruiting

  • Associated Med Professionals of NY

    Syracuse, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Central Ohio Urology Group

    Gahanna, Ohio · Recruiting

  • Oregon Urology Institute

    Springfield, Oregon · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Texas Oncology

    Dallas, Texas · Recruiting

  • Urology San Antonio

    San Antonio, Texas · Recruiting

  • Utah Intermountain Medical Center

    Murray, Utah · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Onco Hemato Asso of SW Virginia

    Roanoke, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Herston, Queensland, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.